Diagnostic value of TPSA, FPSA, FPSA/TPSA and ferritin for prostate cancer

Objective: To explore the clinical value of determination of the total prostate-associated antigen (TPSA), free prostate-associated antigen (FPSA), FPSA/TPSA ratio and ferritin alone and jointly for prostate cancer. Methods: The concentration of TPSA, FPSA, ferritin and FPSA/TPSA were detected in 94 prostate cancer patients, 103 benign prostatic hyperplasia patients and 104 healthy controls. Results: When the TPSA, FPSA, FPSA/TPSA and Ferr were detected alone to differentiate the benign prostatic hyperplasia and prostate cancer, the best diagnostic indicator was FPSA/TPSA. The diagnostic sensitivity and specificity were 82.3% and 59.8%, respectively. The worst was FPSA, the diagnostic sensitivity and specificity were 69.3% and 52.1%, respectively. When the indicators were used alone for the distinction between PCA and BPH, the diagnostic value cannot meet the clinical need. Binary logistic regression analysis was used for the FPSA, TPSA, FPSA/TPSA and ferritin joint diagnosis. The diagnostic value was greater than that by any indicator alone, the diagnostic sensitivity and specificity were 72.6% and 79.8%, respectively. Conclusion: The joint detection of TPSA, FPSA, FPSA/TPSA and Ferritin could improve the diagnostic value, and can be served as an aided diagnosis method for clinical application. (authors)